POLYCYSTIC OVARY SYNDROME: ORIGINS AND IMPLICATIONS: Gestational anti-Müllerian hormone and testosterone excess combined with maternal adiposity program for polycystic ovary syndrome
Reproduction · 2025
DOI: 10.1530/rep-25-0120 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Reproduction, 2025. Verfasst von David H Abbott und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Anti-Mullerian Hormone, Testosterone, Adiposity. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 169 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NICHD NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
In brief A ‘two hit’ developmental origin involving testosterone and anti-Müllerian hormone is proposed to initiate PCOS pathogenesis during gestation. Epigenetic mechanisms amplify genetically heritable traits, while accompanying metabolic perturbations, including gestational hyperglycemia, hypertension and maternal obesity, exaggerate PCOS expression. Abstract Pre- or perinatal excess of anti-Müllerian hormone (AMH) or testosterone faithfully reproduce many polycystic ovary syndrome (PCOS)-like reproductive and metabolic traits in animal models. Epigenetic transgenerational transmission of such developmental programming has been repeatedly demonstrated in mice and is likely to exist in nonhuman primates. In humans, hyperandrogenic PCOS is reliably heritable and repeatedly associated with >20 PCOS risk genes and altered epigenetic signatures. Infant daughters of women with PCOS exhibit traits consistent with a hyperandrogenic fetal environment that is accompanied by precocious onset of AMH hypersecretion. Elevated AMH levels, likely of ovarian origin, persist from birth through adolescence in daughters of women with PCOS, and in adult women with PCOS, and associate with extending the reproductive years and delaying peri-menopause. Evidence is accumulating for fetal extra-ovarian production and action of AMH in various tissues: the brain, for survival of GnRH neurons migrating from the embryonic nose to the hypothalamus; the pituitary, for gonadotrope development; and the placenta, for optimal fetal support. In addition, PCOS risk genes, including those regulating androgen biosynthesis, are being identified in many families with PCOS, bestowing the potential for intrinsic androgen excess in the fetal ovary, adrenal, brain, abdominal adipose and pilosebaceous glands. A ‘two hit’ developmental origin may therefore promote PCOS pathogenesis during gestation when epigenetic mechanisms amplify genetically heritable traits, while accompanying metabolic perturbations, including gestational hyperglycemia, hypertension and maternal obesity, may exaggerate the phenotypic expression of PCOS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
ORCID-Profile: David H Abbott, Daniel A Dumesic
Förderung
- NIH HHS
- NICHD NIH HHS
- NIDDK NIH HHS
- NCATS NIH HHS
- NCRR NIH HHS
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- National Center for Advancing Translational Sciences
Zitieren
APA
Abbott, D. H., Levine, J. E., Dumesic, P. A., Padmanabhan, V., & Dumesic, D. A. (2025). POLYCYSTIC OVARY SYNDROME: ORIGINS AND IMPLICATIONS: Gestational anti-Müllerian hormone and testosterone excess combined with maternal adiposity program for polycystic ovary syndrome. Reproduction. https://doi.org/10.1530/rep-25-0120
Vancouver
Abbott DH, Levine JE, Dumesic PA, Padmanabhan V, Dumesic DA. POLYCYSTIC OVARY SYNDROME: ORIGINS AND IMPLICATIONS: Gestational anti-Müllerian hormone and testosterone excess combined with maternal adiposity program for polycystic ovary syndrome. Reproduction. 2025. doi:10.1530/rep-25-0120
BibTeX
@article{Abbott2025,
author = {Abbott, David H and Levine, Jon E and Dumesic, Phillip A and Padmanabhan, Vasantha and Dumesic, Daniel A},
title = {POLYCYSTIC OVARY SYNDROME: ORIGINS AND IMPLICATIONS: Gestational anti-Müllerian hormone and testosterone excess combined with maternal adiposity program for polycystic ovary syndrome},
journal = {Reproduction},
year = {2025},
doi = {10.1530/rep-25-0120}
}
EUVIMED